GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Adynxx Inc (FRA:HL1C) » Definitions » Cyclically Adjusted PS Ratio

Adynxx (FRA:HL1C) Cyclically Adjusted PS Ratio : (As of Jun. 11, 2024)


View and export this data going back to 1998. Start your Free Trial

What is Adynxx Cyclically Adjusted PS Ratio?

Note: If the price history is too short, we do not calculate current Cyclically Adjusted PS Ratio for this stock. All the historical data is shown as the company's primary share's data instead.

Shiller PE for Stocks: The True Measure of Stock Valuation


Adynxx Cyclically Adjusted PS Ratio Historical Data

The historical data trend for Adynxx's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Adynxx Cyclically Adjusted PS Ratio Chart

Adynxx Annual Data
Trend Dec09 Dec10 Dec11 Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Adynxx Quarterly Data
Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Adynxx's Cyclically Adjusted PS Ratio

For the Biotechnology subindustry, Adynxx's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Adynxx's Cyclically Adjusted PS Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Adynxx's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Adynxx's Cyclically Adjusted PS Ratio falls into.



Adynxx Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

Adynxx's Cyclically Adjusted Revenue per Share for the quarter that ended in Sep. 2019 is calculated as:

For example, Adynxx's adjusted Revenue per Share data for the three months ended in Sep. 2019 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Sep. 2019 (Change)*Current CPI (Sep. 2019)
=0/108.3294*108.3294
=0.000

Current CPI (Sep. 2019) = 108.3294.

Adynxx Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
200912 8.256 91.111 9.816
201003 5.828 91.821 6.876
201006 5.982 91.962 7.047
201009 2.829 92.162 3.325
201012 3.947 92.474 4.624
201103 3.727 94.283 4.282
201106 7.456 95.235 8.481
201109 3.813 95.727 4.315
201112 1.525 95.213 1.735
201203 1.762 96.783 1.972
201206 2.341 96.819 2.619
201209 3.222 97.633 3.575
201212 3.177 96.871 3.553
201303 3.061 98.209 3.376
201306 3.635 98.518 3.997
201309 2.780 98.790 3.048
201312 2.235 98.326 2.462
201403 2.073 99.695 2.253
201406 3.004 100.560 3.236
201409 4.441 100.428 4.790
201412 5.153 99.070 5.635
201503 7.287 99.621 7.924
201506 6.024 100.684 6.481
201509 8.305 100.392 8.962
201512 8.044 99.792 8.732
201603 7.809 100.470 8.420
201606 8.353 101.688 8.899
201609 8.294 101.861 8.821
201612 8.962 101.863 9.531
201703 7.533 102.862 7.933
201706 0.727 103.349 0.762
201709 0.529 104.136 0.550
201712 0.704 104.011 0.733
201803 0.615 105.290 0.633
201806 1.007 106.317 1.026
201809 0.359 106.507 0.365
201812 0.486 105.998 0.497
201903 0.137 107.251 0.138
201906 0.000 108.070 0.000
201909 0.000 108.329 0.000

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Adynxx  (FRA:HL1C) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


Adynxx Cyclically Adjusted PS Ratio Related Terms

Thank you for viewing the detailed overview of Adynxx's Cyclically Adjusted PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Adynxx (FRA:HL1C) Business Description

Industry
Traded in Other Exchanges
N/A
Address
100 Pine Street, Suite 500, San Francisco, CA, USA, 94111
Adynxx Inc is a United States-based clinical-stage biopharmaceutical company. It is focused on the development of a new class of therapeutics called transcription factor decoys and bringing to the market novel, disease-modifying products to address unmet needs in the treatment of pain and inflammation. Its pipeline includes brivoligide, a Phase 2 drug candidate intended to address postoperative pain, and AYX2, a pre-clinical candidate intended to treat chronic syndromes of pain, including both inflammatory and neuropathic pain.

Adynxx (FRA:HL1C) Headlines

No Headlines